Sonia A Perez

Summary

Affiliation: Cancer Immunology and Immunotherapy Center
Country: Greece

Publications

  1. doi request reprint AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial
    Sonia A Perez
    Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Building No 2, 3rd Floor, 171 Alexandras Avenue, 11522, Athens, Greece
    Cancer Immunol Immunother 62:1599-608. 2013
  2. ncbi request reprint Effect of IL-21 on NK cells derived from different umbilical cord blood populations
    Sonia A Perez
    Cancer Immunology and Immunotherapy Center, Saint Savas Hospital, 171 Alexandras Avenue, Athens 115 22, Greece
    Int Immunol 18:49-58. 2006
  3. ncbi request reprint A potential role for hydrocortisone in the positive regulation of IL-15-activated NK-cell proliferation and survival
    Sonia A Perez
    Cancer Immunology and Immunotherapy Center, Saint Savas Hospital, 171 Alexandras Ave, Athens 115 22, Greece
    Blood 106:158-66. 2005
  4. ncbi request reprint CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients
    Sonia A Perez
    Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece
    Clin Cancer Res 13:2714-21. 2007
  5. ncbi request reprint A novel myeloid-like NK cell progenitor in human umbilical cord blood
    Sonia A Perez
    Cancer Immunology Immunotherapy Center, Saint Savas Hospital, Athens, Greece
    Blood 101:3444-50. 2003
  6. doi request reprint HER-2/neu as a target for cancer vaccines
    Constantin N Baxevanis
    Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece
    Immunotherapy 2:213-26. 2010
  7. doi request reprint Identification and characterization of a HER-2/neu epitope as a potential target for cancer immunotherapy
    Eftychia Lekka
    Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece
    Cancer Immunol Immunother 59:715-27. 2010
  8. ncbi request reprint Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors
    Nectaria N Sotiriadou
    Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece
    Cancer Immunol Immunother 56:601-13. 2007
  9. ncbi request reprint Increased frequency of CD4+ cells expressing CD161 in cancer patients
    Eleni G Iliopoulou
    Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece
    Clin Cancer Res 12:6901-9. 2006
  10. ncbi request reprint CRD-BP/IMP1 expression characterizes cord blood CD34+ stem cells and affects c-myc and IGF-II expression in MCF-7 cancer cells
    Panayotis Ioannidis
    Cancer Immunology Immunotherapy Center, Saint Savas Hospital, Athens, Greece
    J Biol Chem 280:20086-93. 2005

Collaborators

Detail Information

Publications50

  1. doi request reprint AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial
    Sonia A Perez
    Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Building No 2, 3rd Floor, 171 Alexandras Avenue, 11522, Athens, Greece
    Cancer Immunol Immunother 62:1599-608. 2013
    ..We suggest that more boosters and/or concomitant disarming of suppressor circuits may be necessary to sustain immunological memory, and therefore, further studies to optimize the AE37 booster schedule are warranted...
  2. ncbi request reprint Effect of IL-21 on NK cells derived from different umbilical cord blood populations
    Sonia A Perez
    Cancer Immunology and Immunotherapy Center, Saint Savas Hospital, 171 Alexandras Avenue, Athens 115 22, Greece
    Int Immunol 18:49-58. 2006
    ..Our data ascribe to IL-21 an essential role on NK cell development and function under conditions similar to the in vivo CB microenvironment...
  3. ncbi request reprint A potential role for hydrocortisone in the positive regulation of IL-15-activated NK-cell proliferation and survival
    Sonia A Perez
    Cancer Immunology and Immunotherapy Center, Saint Savas Hospital, 171 Alexandras Ave, Athens 115 22, Greece
    Blood 106:158-66. 2005
    ..Our data ascribe a novel role to GCs on mature NK-cell expansion and function and open new perspectives for their use in cellular adoptive cancer immunotherapy...
  4. ncbi request reprint CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients
    Sonia A Perez
    Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece
    Clin Cancer Res 13:2714-21. 2007
    ..Circulating Tregs in correlation with HER-2/neu (HER) status and treatment with chemotherapy, either alone or in combination with trastuzumab therapy, were monitored in advanced-stage breast cancer patients...
  5. ncbi request reprint A novel myeloid-like NK cell progenitor in human umbilical cord blood
    Sonia A Perez
    Cancer Immunology Immunotherapy Center, Saint Savas Hospital, Athens, Greece
    Blood 101:3444-50. 2003
    ..Approximately 60% of the CD56(+) derived from the UCB/ACF or the UCB/CD14(+) cells coexpressed CD14 by day 5. Taken together, our data support the role of CD14(+) myeloid-like cells within UCB as a novel progenitor for lymphoid NK cells...
  6. doi request reprint HER-2/neu as a target for cancer vaccines
    Constantin N Baxevanis
    Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece
    Immunotherapy 2:213-26. 2010
    ..Future approaches include multiepitope preventive vaccines and combinatorial treatments for generating the most efficient protective anti-tumor immunity...
  7. doi request reprint Identification and characterization of a HER-2/neu epitope as a potential target for cancer immunotherapy
    Eftychia Lekka
    Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece
    Cancer Immunol Immunother 59:715-27. 2010
    ..A2.1.HER tumors, inducing complete tumor regression in 50% of mice. Our data encourage further exploitation of HER-2(9(828)) as a promising candidate for peptide-based cancer vaccines...
  8. ncbi request reprint Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors
    Nectaria N Sotiriadou
    Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece
    Cancer Immunol Immunother 56:601-13. 2007
    ....
  9. ncbi request reprint Increased frequency of CD4+ cells expressing CD161 in cancer patients
    Eleni G Iliopoulou
    Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece
    Clin Cancer Res 12:6901-9. 2006
    ..In the present study, we examined T cells expressing CD161 in the peripheral blood, the tumor tissue and in malignant effusions of patients with several types of malignancies...
  10. ncbi request reprint CRD-BP/IMP1 expression characterizes cord blood CD34+ stem cells and affects c-myc and IGF-II expression in MCF-7 cancer cells
    Panayotis Ioannidis
    Cancer Immunology Immunotherapy Center, Saint Savas Hospital, Athens, Greece
    J Biol Chem 280:20086-93. 2005
    ....
  11. doi request reprint HER-2/neu (657-665) represents an immunogenic epitope of HER-2/neu oncoprotein with potent antitumor properties
    Angelos D Gritzapis
    Cancer Immunology and Immunotherapy Center, St Savas Hospital, Athens, Greece
    Vaccine 28:162-70. 2009
    ..1(+) patients with HER-2/neu(+) breast cancer. Our data encourage further exploitation of HER-2(9(657)) as a promising candidate for peptide-based cancer vaccines...
  12. doi request reprint A new era in anticancer peptide vaccines
    Sonia A Perez
    Cancer Immunology and Immunotherapy Center, St Savas Cancer Hospital, Athens, Greece
    Cancer 116:2071-80. 2010
    ..Finally, therapeutic CD8-positive T-cell peptide vaccines have been improved by coimmunization with T-helper epitopes expressed on long peptides...
  13. ncbi request reprint Immunogenic HER-2/neu peptides as tumor vaccines
    Constantin N Baxevanis
    Cancer Immunology and Immunotherapy Center, St Savas Hospital, 171 Alexandras Ave, 11522, Athens, Greece
    Cancer Immunol Immunother 55:85-95. 2006
    ..Vaccine preparations containing mixtures of HER-2/neu peptides and peptide from other tumor-related antigens might also enhance efficacy of therapeutic vaccination...
  14. doi request reprint NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses
    Maria Salagianni
    Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens 115 22, Greece
    J Immunol 186:3327-35. 2011
    ....
  15. ncbi request reprint Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo
    Angelos D Gritzapis
    Cancer Immunology and Immunotherapy Center, St Savas Cancer Hospital, Athens, Greece
    Cancer Res 66:5452-60. 2006
    ....
  16. doi request reprint Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer
    Sonia A Perez
    Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece
    Clin Cancer Res 16:3495-506. 2010
    ..The primary end points of the study were to evaluate toxicity and monitor patients' immune responses to the vaccine...
  17. ncbi request reprint Natural CD8+ T-cell responses against MHC class I epitopes of the HER-2/ neu oncoprotein in patients with epithelial tumors
    Panagiota A Sotiropoulou
    Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, 171 Alexandras Avenue, 115 22 Athens, Greece
    Cancer Immunol Immunother 52:771-9. 2003
    ..Our findings broaden the potential application of HER-2/ neu-based immunotherapy...
  18. ncbi request reprint Beneficial effect of short-term exposure of human NK cells to IL15/IL12 and IL15/IL18 on cell apoptosis and function
    Nectaria N Sotiriadou
    Cancer Immunology and Immunotherapy Center, Saint Savas Hospital, Athens, Greece
    Cell Immunol 234:67-75. 2005
    ..In conclusion, short-term exposure of CD56+ cells to IL15/IL12 or IL15/IL18 at 8-day intervals may hold a promise for improved clinical results in cellular adoptive cancer immunotherapy and for the in vivo injections of the monokines...
  19. ncbi request reprint In vitro and in vivo antitumor activity of a mouse CTL hybridoma expressing chimeric receptors bearing the single chain Fv from HER-2/neu- specific antibody and the gamma-chain from Fc(epsilon) RI
    Avgi Mamalaki
    Department of Biochemistry, Hellenic Pasteur Institute, Athens, Greece
    Cancer Immunol Immunother 52:513-22. 2003
    ..Moreover, they open the possibility of using the same chimeric gene for transducing primary lymphocytes and thus allowing adoptive immunotherapy against HER-2/neu(+) cancers...
  20. doi request reprint A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer
    Eleni G Iliopoulou
    Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, 171 Alexandras Avenue, 115 22, Athens, Greece
    Cancer Immunol Immunother 59:1781-9. 2010
    ..In conclusion, repetitive infusions of allogeneic, in vitro activated and expanded with IL-15/HC NK cells, in combination with chemotherapy are safe and potentially clinically effective...
  21. doi request reprint Effects of donor age, gender, and in vitro cellular aging on the phenotypic, functional, and molecular characteristics of mouse bone marrow-derived mesenchymal stem cells
    Olga Katsara
    Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece
    Stem Cells Dev 20:1549-61. 2011
    ..These findings could further support the extrinsic theory of aging of the MSC population and the potential implication of embryonic genes in adult stem cell physiology...
  22. doi request reprint Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy
    Constantin N Baxevanis
    Cancer Immunology and Immunotherapy Center, St Savas Cancer Hospital, Athens, Greece
    Cancer Immunol Immunother 58:317-24. 2009
    ....
  23. ncbi request reprint Interactions between human mesenchymal stem cells and natural killer cells
    Panagiota A Sotiropoulou
    Cancer Immunology and Immunotherapy Center, Saint Savas Hospital, 171 Alexandras Ave, 115 22, Athens, Greece
    Stem Cells 24:74-85. 2006
    ....
  24. ncbi request reprint Natural killer lymphocytes: biology, development, and function
    Michael Papamichail
    Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, 171 Alexandras Avenue, 115 22, Athens, Greece
    Cancer Immunol Immunother 53:176-86. 2004
    ..The marked progress in our understanding of the biology, development, and function of NK/NKT cells has provided the basis for their potential application in tumor clinical trials...
  25. doi request reprint Gamma-irradiation induces HER-2/neu overexpression in breast cancer cell lines and sensitivity to treatment with trastuzumab
    Ioannis F Voutsas
    Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece
    Int J Radiat Biol 89:319-25. 2013
    ....
  26. doi request reprint Effect of the simultaneous administration of glucocorticoids and IL-15 on human NK cell phenotype, proliferation and function
    Ardiana Moustaki
    Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, 171 Alexandras Avenue, 11522 Athens, Greece
    Cancer Immunol Immunother 60:1683-95. 2011
    ....
  27. doi request reprint A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit
    Eleftheria A Anastasopoulou
    Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, 171 Alexandras Avenue, 11522, Athens, Greece
    Cancer Immunol Immunother 64:1123-36. 2015
    ..These data suggest that HLA-DRB1*11 and HLA-A*24 are likely to be predictive factors for immunological and clinical responses to vaccination with AE37, though prospective validation in larger cohorts is needed...
  28. doi request reprint IGF2BP1 expression in human mesenchymal stem cells significantly affects their proliferation and is under the epigenetic control of TET1/2 demethylases
    Louisa G Mahaira
    1 Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece
    Stem Cells Dev 23:2501-12. 2014
    ..These results indicate that IGF2BP1 and TET1/2 contribute to the stemness of MSCs, at least regarding their proliferative potential. ..
  29. ncbi request reprint HER-2/neu-derived peptide 884-899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4(+) T cell clones
    Sonia A Perez
    Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, 171 Alexandras Avenue, 115 22 Athens, Greece
    Cancer Immunol Immunother 50:615-24. 2002
    ..Our results suggest that HER-2(884-899) might be attractive for broadly applicable vaccines and may prove useful for adoptive immunotherapy designed for breast, colorectal and pancreatic carcinomas...
  30. ncbi request reprint Clinical grade expansion of human bone marrow mesenchymal stem cells
    Panagiota A Sotiropoulou
    Cancer Immunology and Immunotherapy Center, Saint Savas Hospital, Athens, Greece
    Methods Mol Biol 407:245-63. 2007
    ..Detailed protocols for fetal calf serum selection and other culture parameters that affect the final outcome are described...
  31. ncbi request reprint Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stem cells
    Panagiota A Sotiropoulou
    Cancer Immunology and Immunotherapy Center, Saint Savas Hospital, 171 Alexandras Avenue, 115 22, Athens, Greece
    Stem Cells 24:462-71. 2006
    ..In conclusion, in this report we define the optimal culture conditions for the successful isolation and expansion of human MSCs in high numbers for subsequent cellular therapeutic approaches...
  32. pmc Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide
    Ioannis F Voutsas
    Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece
    J Immunother Cancer 4:75. 2016
    ..Additionally, we investigated the ability of the AE37 vaccine to induce an antitumor immune response against other tumor associated antigens, not integrated in the vaccine formulation, with respect to the clinical response...
  33. doi request reprint Mannose addition by yeast Pichia Pastoris on recombinant HER-2 protein inhibits recognition by the monoclonal antibody herceptin
    Spiros Vlahopoulos
    Immunology Center, St Savas Cancer Hospital, Athens, Greece
    Vaccine 27:4704-8. 2009
    ..The extensive glycosylation of HER-2 in Pichia Pastoris significantly increases its recognition and uptake by dendritic cells, which could be associated with increased vaccine performance...
  34. ncbi request reprint Characterization of a novel cell penetrating peptide derived from Bag-1 protein
    Dimitrios K Niarchos
    Cancer Immunology and Immunotherapy Center, Saint Savas Hospital, Athens 11522, Greece
    Peptides 27:2661-9. 2006
    ..Finally, BagP internalization depends on its charge, cellular metabolism and cell-surface heparan sulfate proteoglycans...
  35. pmc MHC class II tetramer analyses in AE37-vaccinated prostate cancer patients reveal vaccine-specific polyfunctional and long-lasting CD4(+) T-cells
    Eleftheria A Anastasopoulou
    Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece
    Oncoimmunology 5:e1178439. 2016
    ..This is the first report on the identification of vaccine-induced HER2-specific multifunctional long-lasting CD4(+) T cells in vaccinated prostate cancer patients. ..
  36. ncbi request reprint Potential Prognostic Molecular Signatures in a Preclinical Model of Melanoma
    Sotirios P Fortis
    Cancer Immunology and Immunotherapy Center, Saint Savvas Cancer Hospital, Athens, Greece
    Anticancer Res 37:143-148. 2017
    ..The concomitant overexpression of key molecules such as IGF2BP1, PTMA, MYC and MITF could serve as prognostic or predictive marker...
  37. doi request reprint Immune biomarkers: how well do they serve prognosis in human cancers?
    Constantin N Baxevanis
    Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, 171 Alexandras Avenue, Athens 11522, Greece
    Expert Rev Mol Diagn 15:49-59. 2015
    ....
  38. doi request reprint Cancer immunotherapy
    Constantin N Baxevanis
    Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece
    Crit Rev Clin Lab Sci 46:167-89. 2009
    ....
  39. doi request reprint AE37 peptide vaccination in prostate cancer: identification of biomarkers in the context of prognosis and prediction
    Sonia A Perez
    Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, 171 Alexandras Avenue, Athens, 11522, Greece
    Cancer Immunol Immunother 63:1141-50. 2014
    ..These retrospective analyses suggest that the above biomarkers at the time-points measured offer promise for evaluating immunologic and clinical responses to AE37-based vaccinations. ..
  40. ncbi request reprint New use for old drugs? Prospective targets of chloroquines in cancer therapy
    Spiros Vlahopoulos
    Horemio Research Institute, First Department of Pediatrics, University of Athens Medical School, Aghia Sophia Children s Hospital, Thivon and Levadias, 11527 Goudi, Athens, Greece
    Curr Drug Targets 15:843-51. 2014
    ..In this review we present some features that are common between cancers that are sensitive to quinoline derivatives, in particular features that are amenable to pharmaceutical intervention...
  41. doi request reprint Invariant chain-peptide fusion vaccine using HER-2/neu
    Sonia A Perez
    Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece
    Methods Mol Biol 1139:321-36. 2014
    ..Also provided is a detailed information about their in vivo administration and analysis of in-depth protocols for monitoring of immune activation upon vaccination with AE37...
  42. doi request reprint Cancer immunotherapy: perspectives and prospects
    Sonia A Perez
    Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece
    Adv Exp Med Biol 622:235-53. 2008
  43. doi request reprint Prostate cancer vaccines: the long road to clinical application
    Constantin N Baxevanis
    Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, 171 Alexandras Avenue, 11522, Athens, Greece
    Cancer Immunol Immunother 64:401-8. 2015
    ....
  44. doi request reprint Therapeutic cancer vaccines: a long and winding road to success
    Constantin N Baxevanis
    St Savas Cancer Hospital, Cancer Immunology and Immunotherapy Center, 171 Alexandras Avenue, 11522 Athens, Greece
    Expert Rev Vaccines 13:131-44. 2014
    ..This review focuses on promising vaccination platforms and essential perspectives in the treatment of cancer. ..
  45. doi request reprint Immune classification of colorectal cancer patients: impressive but how complete?
    Constantin N Baxevanis
    Saint Savas Cancer Hospital, Cancer Immunology and Immunotherapy Center, 171 Alexandras Avenue, Athens, 11522, Greece
    Expert Opin Biol Ther 13:517-26. 2013
    ..Recent exciting studies of human colorectal cancers (CRCs) have underlined the significance of including immunological biomarkers as prognostic markers...
  46. ncbi request reprint Transcoronary transplantation of autologous mesenchymal stem cells and endothelial progenitors into infarcted human myocardium
    Demosthenes G Katritsis
    Department of Cardiology, Athens Euroclinic, Athens, Greece
    Catheter Cardiovasc Interv 65:321-9. 2005
    ..Intracoronary transplantation of MSCs and EPCs is feasible, safe, and may contribute to regional regeneration of myocardial tissue early or late following MI...
  47. pmc Cancer Dormancy: A Regulatory Role for Endogenous Immunity in Establishing and Maintaining the Tumor Dormant State
    Constantin N Baxevanis
    Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, 171 Alexandras Avenue, Athens 11522, Greece
    Vaccines (Basel) 3:597-619. 2015
    ..In this review, we mean to suggest that anticancer therapies aiming to stimulate the endogenous antitumor responses provide the concept of the therapeutic management of cancer. ..
  48. ncbi request reprint Cell culture medium composition and translational adult bone marrow-derived stem cell research
    Panagiota A Sotiropoulou
    Stem Cells 24:1409-10. 2006
    ..Finally, vast numbers of MSCs cultured in FCS-containing media have already been used in many clinical trials targeting a variety of disorders, without any significant side effects, including ventricular arrhythmia...
  49. ncbi request reprint A HER-2/neu peptide admixed with PLA microspheres induces a Th1-biased immune response in mice
    Konstantina N Nikou
    Mass Spectrometry and Dioxin Analysis Laboratory, IRRP, National Centre for Scientific Research Demokritos, 15310 Athens, Greece
    Biochim Biophys Acta 1725:182-9. 2005
    ....